CTIC - CTI BioPharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.99
+0.04 (+2.05%)
At close: 4:00PM EDT

1.99 0.00 (0.00%)
After hours: 4:52PM EDT

Stock chart is not supported by your current browser
Previous Close1.95
Open1.92
Bid1.90 x 1800
Ask2.05 x 3000
Day's Range1.90 - 2.01
52 Week Range1.70 - 5.36
Volume198,953
Avg. Volume540,649
Market Cap115.382M
Beta (3Y Monthly)-1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateFeb 28, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
Trade prices are not sourced from all markets
  • Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?
    Zacks17 days ago

    Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?

    Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

  • PR Newswire18 days ago

    CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review

    SEATTLE, Oct. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monitoring Committee (IDMC), the study will continue to the full enrollment of 150 patients. The IDMC did not identify significant drug- or dose-related safety concerns and specifically did not identify any concerns around hemorrhagic or cardiac toxicity.

  • CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
    PR Newswire23 days ago

    CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3

    SEATTLE , Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare ...

  • ACCESSWIRE3 months ago

    CTI BioPharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / CTI BioPharma Corp. (NASDAQ: CTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. ...

  • CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

    CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.04% and 104.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    CTI BioPharma: 2Q Earnings Snapshot

    The Seattle-based company said it had a loss of 20 cents per share. The biotechnology company posted revenue of $613,000 in the period. The company's shares closed at $2.25. A year ago, they were trading ...

  • CTI BioPharma Reports Second Quarter 2018 Financial Results
    PR Newswire3 months ago

    CTI BioPharma Reports Second Quarter 2018 Financial Results

    -Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE , Aug. 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter ...

  • CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
    PR Newswire3 months ago

    CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018

    SEATTLE , July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results on Thursday, August ...

  • CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
    Zacks3 months ago

    CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA

    CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Shares of CTI Biopharma tanked nearly 44% yesterday while shares of Crinetics Pharmaceuticals exploded 44%. The former announced an update from an FDA meeting regarding the company's investigational drug pacritinib. Per FDA feedback, the company will now have to conduct a Phase 3 trial.

  • CTI BioPharma Has Fallen Almost 39% Today
    Market Realist3 months ago

    CTI BioPharma Has Fallen Almost 39% Today

    Why Is CTI BioPharma Stock Down Today? On July 18, CTI BioPharma (CTIC) announced the outcome of its type B meeting with the FDA related to its investigational drug pacritinib. As per the FDA’s feedback, the company now needs to conduct a Phase 3 trial to evaluate this second-generation JAK2 inhibitor for the treatment of myelofibrosis patients suffering from thrombocytopenia or who have already been treated with ruxolitinib.

  • Why CTI BioPharma Corp. Crashed Today
    Motley Fool3 months ago

    Why CTI BioPharma Corp. Crashed Today

    The FDA's requirement of a new late-stage clinical study caused the biotech stock to plunge.

  • PR Newswire3 months ago

    CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA

    SEATTLE, July 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory pathway for pacritinib. Based on FDA feedback, the Company plans to conduct a randomized Phase 3 study in patients with myelofibrosis.

  • Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
    Zacks3 months ago

    Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

    Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

  • CTI BioPharma Falls After Failure of Pivotal Lymphoma Study
    Zacks3 months ago

    CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

    CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.

  • Why CTI BioPharma, PetMed Express, and Pfizer Slumped Today
    Motley Fool3 months ago

    Why CTI BioPharma, PetMed Express, and Pfizer Slumped Today

    Read on to see which of these companies drew the ire of Donald Trump.

  • Associated Press3 months ago

    Groupon, JPMorgan Chase rise, Twitter, CTI BioPharma fall

    Stocks that moved substantially or traded heavily Monday: Groupon Inc., up 47 cents to $4.83 Recode reported that the online coupon company is looking for a buyer. Twitter Inc., down $2.51 to $44.14 The ...

  • Why CTI BioPharma Corp. Is Sinking Today
    Motley Fool3 months ago

    Why CTI BioPharma Corp. Is Sinking Today

    Shares tumble in response to disappointing clinical news. Here's what investors need to know.

  • Reuters3 months ago

    CTI Biopharma's cancer drug fails late-stage trial

    CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. The drug, Pixuvri, did not show a statistically significant improvement in the length of time patients survived without any progression in the disease. CTI's treatment was being tested in combination with Roche Holding's Rituxan in patients with aggressive B-cell Non-Hodgkin lymphoma.

  • Reuters3 months ago

    CTI Biopharma's cancer treatment fails to meet trial goal

    CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. The drug, Pixuvri, was being tested in patients with aggressive B-cell Non-Hodgkin ...